Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors-Reference-Cited by-全球学者库

Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors

Published:2017-03 Issue:5 Volume:195 Page:663-673
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Chang I-Shou¹,Jiang Shih Sheng¹,Yang James Chih-Hsin²³,Su Wu-Chou⁴,Chien Li-Hsin⁵,Hsiao Chin-Fu⁵⁶,Lee Jih-Hsiang²,Chen Chih-Yi⁷⁸,Chen Chung-Hsing¹,Chang Gee-Chen⁹¹⁰,Wang Zhaoming¹¹,Lo Fang-Yi⁵,Chen Kuan-Yu¹²,Wang Wen-Chang⁵¹³,Chen Yuh-Min¹⁴¹⁵,Huang Ming-Shyan¹⁶,Tsai Ying-Huang¹⁷,Su Yu-Chun⁵,Hsieh Wan-Shan⁵,Shih Wen-Chi⁵,Shieh Shwn-Huey¹⁸¹⁹,Yang Tsung-Ying¹⁰,Lan Qing²⁰,Rothman Nathaniel²⁰,Chen Chien-Jen²¹,Chanock Stephen J.²⁰,Yang Pan-Chyr²²,Hsiung Chao A.⁵

Affiliation:

1. National Institute of Cancer Research

2. Department of Oncology and

3. Graduate Institute of Oncology and Cancer Research Center, College of Medicine and

4. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

5. Institute of Population Health Sciences, and

6. Taiwan Lung Cancer Tissue/Specimen Information Resource Center, National Health Research Institutes, Zhunan, Taiwan

7. Institute of Medicine and

8. Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan

9. Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

10. Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

11. Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, and

12. Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan

13. The Ph.D. Program for Translational Medicine, College of Medical Science and Technology and

14. College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

15. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

16. Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

17. Division of Pulmonary and Critical Care Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

18. Department of Health Services Administration and

19. Department of Nursing, China Medical University, Taichung, Taiwan; and

20. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

21. Genomic Research Center, Academia Sinica, Taipei, Taiwan

22. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference28 articles.

1. Cancer Statistics, 2009

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

5. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of TDP-43 in non-neuronal systems;Cell Communication and Signaling;2023-11-23

2. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population;Nature Communications;2023-05-26

3. Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression;PLOS Genetics;2023-02-23

4. Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for Taiwan;Cancer Epidemiology, Biomarkers & Prevention;2022-09-21

5. Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer;Translational Lung Cancer Research;2022-09